YEM Search

搜索结果

TSC2

靶点ID:TCMBANKGE000447

靶点别名:LAM; PPP1R160; TSC4

靶点描述:TSC complex subunit 2

染色体:16

染色体位置:16p13.3

靶点类型:protein-coding

HERB_ID:-

HGNC_Link:12363

OMIM_Link:191092

Ensembl_Link:ENSG00000103197

靶点对应的植物

ID	拉丁名	药名	药用植物名	功能与主治	来源	药用部位	使用民族

靶点对应的化合物

化合物ID	化合物名	别名	分子式	分子质量	Smiles

TCMBANKIN012700	coumestrol	NCIMech_000078; CCRIS 7311; A-Lactone; API0002121; Tox21_200032; MolPort-003-846-031; US8552057, 3; HMS3374A07; 3,9-Dihydroxy-6H-benzofuro[3,2-c]-[1]benzopyran-6-one; 6H-Benzofuro[3,2-c][1]benzopyran-6-one,3,9-dihydroxy-; Cumostrol; CHEBI:3908; C-16836; VZ31590; LS-35394; S00280; 3,9-dihydroxy-[1]benzofuro[3,2-c]chromen-6-one; MFCD00016885; SMP2_000163; DSSTox_RID_76572; 27885_FLUKA; 6H-Benzofuro[3, 3,9-dihydroxy-; 5-19-06-00405 (Beilstein Handbook Reference); BRN 0266702; 479-13-0; NSC22842; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, delta-lactone; C10205; 3,9-dihydroxy-[1]benzoxolo[3,2-c]chromen-6-one; AC1NQYXV; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, delta-lactone (6CI); NCGC00018124-01; DSSTox_CID_2399; CTK8F8799; Coumestrol, >=95.0% (HPLC); NCI60_001863; 4CN-2508; ZZIALNLLNHEQPJ-UHFFFAOYSA-N; BIDD:ER0114; NCGC00018124-03; 3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one #; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-; A1-00298; NSC 22842; 3,9-Dihydroxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one; CCG-35536; NCGC00018124-06; 3,9-bis(oxidanyl)-[1]benzofuro[3,2-c]chromen-6-one; ZINC1219; NCGC00257586-01; 3,9-Dihydroxy-benzo[4,5]furo[3,2-c]chromen-6-one; AIDS011954; SCHEMBL22012; UNII-V7NW98OB34; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, .delta.-lactone; 6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-; MLS000069446; CCG-36200; LMPK12090018; 3-Benzofurancarboxylic acid,4-dihydroxyphenyl)-6-hydroxy-, .delta.-lactone; 7,12-Dihydroxycoumestan; CS-6343; D02DML; CHEMBL30707; 3,9-dihydroxy-6-benzofurano[3,2-c]chromenone; ZINC00001219; 5,14-dihydroxy-8,17-dioxatetracyclo[8.7.0.0^{2,7}.0^{11,16}]heptadeca-1(10),2,4,6,11(16),12,14-heptaen-9-one; Oprea1_222511; MLS000738006; EINECS 207-525-6; 3,9-Dihydroxycoumestan; Coumestrol, BioReagent, suitable for fluorescence, >=97.5% (HPLC); A827386; DTXSID6022399; CAS-479-13-0; FT-0603177; ST50320052; 2-(2,4-Dihydroxyphenyl)-6-hydroxy-3-benzofurancarboxylic Acid ; 3,9-dihydroxybenzofurano[3,2-c]chromen-6-one; 3,9-dihydroxybenzo[d]chromeno[4,3-b]furan-6-one; NCGC00023462-03; AIDS-011954; V0359; Cumoestrol; DSSTox_GSID_22399; Cumoesterol; NCGC00018124-05; Coumestrol; NCGC00018124-04; V7NW98OB34; ZB000278; 3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one; ST5320052; AN-6463; Cumestrol; NCGC00023462-04; NCGC00018124-02; CC-25990; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihdyroxy-; NSC-22842; 3,9-dihydroxybenzofuro[3,2-c]chromen-6-one; AKOS028111776; HMS2235B05; Coumesterol; COUMESTROL; BDBM23451; SMR000059001; HY-N2335; 27883_FLUKA	C15H8O5	268.22	C1=CC2=C(C=C1O)OC3=C2C(=O)OC4=C3C=CC(=C4)O
TCMBANKIN057911	se	selenium	H2Se	78.97 g/mol	[Se]
TCMBANKIN058205	trans-resveratrol	(E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4′,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4′ NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4′,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4′,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene	C14H12O3	228.24 g/mol	C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O
TCMBANKIN059684	Vitamin E β-		C29H50O2	430.79	CC1=C(C(=C2CCC(OC2=C1C)(C)CCCC(C)CCCC(C)CCCC(C)C)C)O
TCMBANKIN059746	α-tocopherol		C29H50O2	430.7 g/mol	CC1=C(C2=C(CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C)C(=C1O)C)C

靶点对应的疾病

疾病ID	疾病名	MeSH名	HPO名	UMLS名	疾病类型

TCMBANKDI000009	Neoplasms	Abnormality of the nervous system; Neoplasm	Neoplastic Process	disease
TCMBANKDI000011	Pathological Conditions, Signs and Symptoms	Abnormality of the digestive system; Constitutional symptom	Sign or Symptom	phenotype
TCMBANKDI000018	Digestive System Diseases; Neoplasms; Endocrine System Diseases	Abnormality of the digestive system; Neoplasm	Neoplastic Process	disease
TCMBANKDI000035	Digestive System Diseases; Infections	-	Disease or Syndrome	disease
TCMBANKDI000049	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases	-	Disease or Syndrome	disease
TCMBANKDI000054	Nervous System Diseases; Mental Disorders	Abnormality of the nervous system	Disease or Syndrome	disease
TCMBANKDI000066	Mental Disorders	Abnormality of the nervous system	Mental or Behavioral Dysfunction	disease
TCMBANKDI000068	Neoplasms; Stomatognathic Diseases	Neoplasm; Abnormality of head or neck	Neoplastic Process	group
TCMBANKDI000076	Neoplasms	-	Neoplastic Process	group
TCMBANKDI000078	Neoplasms; Skin and Connective Tissue Diseases	Abnormality of the integument; Neoplasm	Neoplastic Process	group
TCMBANKDI000088	Neoplasms; Respiratory Tract Diseases	Neoplasm; Abnormality of the respiratory system	Neoplastic Process	group
TCMBANKDI000092	Respiratory Tract Diseases	Abnormality of the respiratory system	Disease or Syndrome	disease
TCMBANKDI000166	-	-	Neoplastic Process	disease
TCMBANKDI002094	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases	Abnormality of the nervous system	Congenital Abnormality	disease
TCMBANKDI002606	Pathological Conditions, Signs and Symptoms; Respiratory Tract Diseases	Abnormality of the respiratory system	Sign or Symptom	phenotype
TCMBANKDI002647	Nervous System Diseases	-	Disease or Syndrome	disease
TCMBANKDI002742	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases	Abnormality of the genitourinary system	Disease or Syndrome	group
TCMBANKDI002974	Neoplasms	-	Neoplastic Process	disease
TCMBANKDI003303	-	-	Disease or Syndrome	disease
TCMBANKDI003353	Pathological Conditions, Signs and Symptoms; Neoplasms	-	Neoplastic Process	phenotype
TCMBANKDI003411	-	-	Disease or Syndrome	disease
TCMBANKDI004134	-	Abnormality of the respiratory system	Finding	phenotype
TCMBANKDI004331	Pathological Conditions, Signs and Symptoms; Nervous System Diseases	-	Disease or Syndrome	phenotype
TCMBANKDI004646	Nervous System Diseases	Abnormality of the nervous system	Disease or Syndrome	disease
TCMBANKDI005272	Pathological Conditions, Signs and Symptoms; Nervous System Diseases	-	Sign or Symptom	phenotype
TCMBANKDI006375	-	Abnormality of the nervous system; Neoplasm	Finding	phenotype
TCMBANKDI006612	Neoplasms; Female Urogenital Diseases and Pregnancy Complications	Abnormality of the genitourinary system; Neoplasm	Neoplastic Process	disease
TCMBANKDI007012	Pathological Conditions, Signs and Symptoms; Nervous System Diseases	-	Pathologic Function	phenotype
TCMBANKDI007341	Infections	-	Disease or Syndrome	disease
TCMBANKDI007468	Infections	-	Disease or Syndrome	phenotype
TCMBANKDI008601	Neoplasms	-	Neoplastic Process	disease
TCMBANKDI009135	Neoplasms	Neoplasm; Abnormality of the skeletal system	Neoplastic Process	disease
TCMBANKDI009231	Pathological Conditions, Signs and Symptoms; Infections	Abnormality of the immune system	Disease or Syndrome	disease
TCMBANKDI009572	Nutritional and Metabolic Diseases	Abnormality of metabolism/homeostasis	Disease or Syndrome	phenotype
TCMBANKDI009702	Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases	Abnormality of the cardiovascular system	Disease or Syndrome	phenotype
TCMBANKDI009749	Respiratory Tract Diseases	Abnormality of the respiratory system	Finding	phenotype
TCMBANKDI009912	Pathological Conditions, Signs and Symptoms	Abnormality of metabolism/homeostasis	Sign or Symptom	phenotype
TCMBANKDI009943	Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases	Abnormality of the cardiovascular system	Disease or Syndrome	disease
TCMBANKDI010160	Respiratory Tract Diseases	Abnormality of the respiratory system	Disease or Syndrome	group
TCMBANKDI010445	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neoplasms; Nervous System Diseases	-	Disease or Syndrome	disease
TCMBANKDI010717	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Eye Diseases	-	Congenital Abnormality	disease
TCMBANKDI011173	Neoplasms	-	Neoplastic Process	disease
TCMBANKDI011481	Neoplasms	Abnormality of the nervous system; Neoplasm	Neoplastic Process	disease
TCMBANKDI011555	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases	Abnormality of the cardiovascular system	Disease or Syndrome	disease
TCMBANKDI011557	Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases	Abnormality of the cardiovascular system	Disease or Syndrome	disease
TCMBANKDI011743	Neoplasms; Skin and Connective Tissue Diseases	Neoplasm; Abnormality of the breast	Neoplastic Process	group
TCMBANKDI011799	Neoplasms; Skin and Connective Tissue Diseases	-	Neoplastic Process	disease
TCMBANKDI012119	Pathological Conditions, Signs and Symptoms	Abnormality of the nervous system	Cell or Molecular Dysfunction	phenotype
TCMBANKDI012238	-	Abnormality of the integument	Finding	phenotype
TCMBANKDI012481	-	-	Disease or Syndrome	disease
TCMBANKDI012932	Infections; Immune System Diseases	-	Disease or Syndrome	group
TCMBANKDI013628	Neoplasms; Skin and Connective Tissue Diseases	-	Neoplastic Process	disease
TCMBANKDI013927	Respiratory Tract Diseases	Abnormality of the respiratory system	Pathologic Function	phenotype
TCMBANKDI014132	Pathological Conditions, Signs and Symptoms; Nervous System Diseases	Abnormality of the nervous system	Disease or Syndrome	disease
TCMBANKDI014740	Pathological Conditions, Signs and Symptoms	Abnormality of the digestive system	Disease or Syndrome	phenotype
TCMBANKDI015452	Neoplasms; Endocrine System Diseases	Abnormality of the endocrine system; Neoplasm	Neoplastic Process	disease
TCMBANKDI015485	Mental Disorders	Abnormality of the nervous system	Mental or Behavioral Dysfunction	disease
TCMBANKDI016026	Neoplasms; Eye Diseases	Neoplasm; Abnormality of the eye	Neoplastic Process	disease
TCMBANKDI016336	Neoplasms	-	Neoplastic Process	disease
TCMBANKDI016443	-	-	Neoplastic Process	disease
TCMBANKDI016872	Neoplasms	-	Disease or Syndrome	disease
TCMBANKDI017024	Neoplasms; Respiratory Tract Diseases	-	Neoplastic Process	disease
TCMBANKDI017355	-	Abnormality of the genitourinary system	Anatomical Abnormality	disease
TCMBANKDI017642	Neoplasms	Abnormality of the integument; Neoplasm	Neoplastic Process	disease
TCMBANKDI018659	Neoplasms	-	Neoplastic Process	group
TCMBANKDI019467	Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases	Abnormality of the genitourinary system; Neoplasm	Neoplastic Process	disease
TCMBANKDI022173	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neoplasms; Musculoskeletal Diseases	-	Neoplastic Process	disease
TCMBANKDI022473	Neoplasms	-	Neoplastic Process	disease
TCMBANKDI023140	Neoplasms; Endocrine System Diseases	Abnormality of the endocrine system; Neoplasm	Neoplastic Process	disease
TCMBANKDI023464	Nervous System Diseases	Abnormality of the nervous system	Disease or Syndrome	disease
TCMBANKDI024057	Pathological Conditions, Signs and Symptoms; Nervous System Diseases	-	Disease or Syndrome	phenotype
TCMBANKDI024403	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases	-	Disease or Syndrome	disease
TCMBANKDI024535	Neoplasms; Respiratory Tract Diseases	Neoplasm; Abnormality of the respiratory system	Neoplastic Process	disease
TCMBANKDI025090	Pathological Conditions, Signs and Symptoms; Respiratory Tract Diseases	Abnormality of the respiratory system	Sign or Symptom	phenotype
TCMBANKDI025447	Nervous System Diseases	Abnormality of the eye	Disease or Syndrome	disease
TCMBANKDI025770	Infections	-	Disease or Syndrome	disease
TCMBANKDI026380	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neoplasms; Skin and Connective Tissue Diseases	Abnormality of the integument; Neoplasm	Neoplastic Process	disease
TCMBANKDI027401	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases	-	Congenital Abnormality	disease
TCMBANKDI027669	-	-	Finding	phenotype
TCMBANKDI028561	Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases	-	Neoplastic Process	disease
TCMBANKDI028870	-	-	Congenital Abnormality	disease
TCMBANKDI029054	Mental Disorders	-	Mental or Behavioral Dysfunction	group
TCMBANKDI029321	Cardiovascular Diseases	-	Disease or Syndrome	group
TCMBANKDI029813	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases	-	Disease or Syndrome	disease
TCMBANKDI030540	Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases	Abnormality of the genitourinary system; Neoplasm	Neoplastic Process	disease
TCMBANKDI030993	Neoplasms; Nervous System Diseases; Cardiovascular Diseases	-	Disease or Syndrome	disease
TCMBANKDI031189	Neoplasms	Neoplasm; Abnormality of the respiratory system	Neoplastic Process	disease
TCMBANKDI031482	-	-	Neoplastic Process	disease
TCMBANKDI031570	-	Abnormality of the nervous system	Mental or Behavioral Dysfunction	disease
TCMBANKDI031754	Pathological Conditions, Signs and Symptoms; Nervous System Diseases	-	Pathologic Function	phenotype
TCMBANKDI032222	Nervous System Diseases; Mental Disorders	-	Mental or Behavioral Dysfunction	disease